OraSure Technologies Appoints Two New Members to the Board of Directors
08 Novembre 2021 - 1:05PM
OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in
point-of-care and home diagnostic testing and sample collection
technologies, announced today the appointment Nancy J. Gagliano,
M.D. and Anne C. Whitaker to the Company’s Board of Directors,
effective November 8, 2021. Dr. Gagliano was a practicing
physician in internal medicine, has extensive retail pharmacy
leadership experience, and was one of the leaders of the RADx Tech,
Rapid Acceleration of Diagnostics program for the National
Institute of Health to bring new diagnostic technologies to market
to counter the global COVID-19 pandemic. Dr. Gagliano will serve as
a Class III Director with an initial term expiring at the Company’s
2024 Annual Meeting of Stockholders. She will also serve on
the Nominating and Corporate Governance Committee of the
Board. Mrs. Whitaker has held numerous board and executive level
positions in the pharmaceutical industry. She has been recognized
by Fierce Pharma as one of the top 25 Most Influential Women in
BioPharma, PharmaVoice as one of the Top 100 most Inspiring Leaders
in Healthcare and Women, Inc. as one of the most Influential
Corporate Directors. She is currently the Chairperson of the
Board of Directors of Aerami Therapeutics. Mrs. Whitaker will serve
as a Class II Director with an initial term expiring at the
Company’s 2023 Annual Meeting of Stockholders. She will also
serve on the Audit Committee of the Board.
“We are exceptionally privileged to bring two
new board members to our team of the caliber and experience of
Nancy and Anne,” said Stephen S. Tang,
Ph.D., President and Chief Executive Officer
of OraSure Technologies. “Their knowledge bases in
critical areas such as global product development, public health,
and the retail pharmacy market will be critical as we look to drive
increased innovation and execute on our long-term global growth
strategy.”
Dr. Gagliano, age 62, has over 35 years of
experience as a senior healthcare physician executive and
practicing physician in internal medicine. Dr. Gagliano most
recently served as an executive leader of the National Institute of
Health’s RADx Tech, Rapid Acceleration of Diagnostics program. In
this position she has helped oversee over one billion dollars of
sponsored programs to bring millions of new COVID-19 tests to
market. Prior to her work for the National Institute of Health, Dr.
Gagliano was the Chief Medical Officer of Culbert Healthcare
Solutions, providing strategic guidance on healthcare consulting
services. Before joining Culbert Healthcare, Dr. Gagliano spent six
years with CVS Health holding senior leadership positions including
as the Chief Medical Officer of Minute Clinic, and as a Senior Vice
President overseeing key programs such as the enterprise smoking
cessation program and the development of the company’s telemedicine
program. Prior to her leadership roles at CVS Health, Dr. Gagliano
was a practicing internal medicine physician and held numerous
leadership positions at Massachusetts General Hospital and
Massachusetts General Physicians Organization.
Dr. Gagliano holds a M.D. from Harvard Medical
School, an MBA from Northeastern University, and a Bachelors of
Science Degree from Union College in Computer Science and
Biology.
Mrs. Whitaker, age 54, is a seasoned healthcare
executive and director with more than 30 years of experience with a
proven track record as an executive of building and leading
high-performance teams. Mrs. Whitaker currently serves as Managing
Partner of Anne Whitaker Group, LLC, a board and private equity
advisory firm, and is the current Chairperson of the Board of
Aerami Therapeutics, a private life science company. Prior to
taking the Chair role at Aerami, Anne served as the CEO from
October 2018 to November 2020 and as a director from July 2018. She
also serves as an independent director on the boards of three
public companies including Faron Pharmaceuticals, a development
stage pharma company; Caladrius, a development stage biotech
company; and Mallinckrodt, a specialty pharmaceutical company. In
addition to her board work, she is an active industry advisor to
private equity and venture capital funds in the US and Europe. Mrs.
Whitaker started her healthcare career with The Upjohn Company
selling pharmaceuticals. She subsequently transitioned to
GlaxoSmithKline PLC where she spent 19 years and rose in the
commercial ranks from a sales representative to become a Senior
Vice President, Business Unit Head for the Cardiovascular,
Metabolic, and Urology franchises in 2009. Anne joined Sanofi SA in
2011 as the President of the North America Pharmaceutical Region.
Anne served as the CEO and President of Synta Pharmaceuticals, Inc.
in 2014 and 2015. She joined Bausch Health as an Executive Vice
President and Company Group Chairman for the Branded
Pharmaceuticals segment in mid-2015. From February 2017 until April
2018 she served as the CEO and President of Novoclem Therapeutics,
Inc.
Mrs. Whitaker holds a Bachelor of Science degree
in chemistry from the University of North Alabama.
About OraSure
TechnologiesOraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. OraSure, together with its
wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis,
provides its customers with end-to-end solutions that encompass
tools, services and diagnostics. The OraSure family of companies is
a leader in the development, manufacture, and distribution of rapid
diagnostic tests, sample collection and stabilization devices, and
molecular services solutions designed to discover and detect
critical medical conditions. OraSure’s portfolio of products is
sold globally to clinical laboratories, hospitals, physician’s
offices, clinics, public health and community-based organizations,
research institutions, government agencies, pharma, commercial
entities and direct to consumers. For more information on OraSure
Technologies, please visit www.orasure.com.
Investor
Contact: |
Media
Contact: |
Scott Gleason |
Amy Koch |
Interim CFO & SVP Investor Relations & Corp.
Communications |
Sr. Mgr. Corporate Communications |
484-425-0588 |
484-523-1815 |
sgleason@orasure.com |
media@orasure.com |
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024